Table 3.
% Undergoing Preoperative Biliary Stenting | p-value | |
---|---|---|
Year of Diagnosis | <0.0001 | |
1992–1995 | 29.6% | |
1996–1999 | 47.1% | |
2000–2003 | 55.9% | |
2004–2007 | 59.1% | |
Patient Demographics | ||
Sex | 0.05 | |
Male | 54.7% | |
Female | 50.9% | |
Race | 0.04 | |
White | 53.7% | |
Black | 45.7% | |
Hispanic | 56.7% | |
Other | 44.6% | |
Marital Status | 0.21 | |
Married | 53.6% | |
Unmarried | 51.1% | |
Charlson comorbidity score | 0.36 | |
0 | 52.2% | |
1 | 51.0% | |
2 | 55.6% | |
3+ | 55.8% | |
Income Quartiles | 0.0006 | |
Quartile 1 (lowest) | 45.6% | |
Quartile 2 | 55.6% | |
Quartile 3 | 55.2% | |
Quartile 4 (highest) | 54.4% | |
Education Quartiles | 0.02 | |
Quartile 1 (lowest) | 47.5% | |
Quartile 2 | 55.6% | |
Quartile 3 | 54.6% | |
Quartile 4 (highest) | 53.2% | |
SEER Region | <0.0001 | |
Atlanta | 53.4% | |
Connecticut | 51.0% | |
Detroit | 44.7% | |
Greater California | 56.5% | |
Hawaii | 40.4% | |
Iowa | 49.2% | |
Kentucky | 62.0% | |
Los Angeles | 47.2% | |
Louisiana | 43.2% | |
New Jersey | 59.3% | |
New Mexico | 45.2% | |
Rural Georgia | 66.7% | |
San Francisco | 46.5% | |
San Jose | 51.6% | |
Seattle | 63.3% | |
Utah | 64.6% | |
Preoperative Signs/Symptoms | ||
Jaundice | <0.0001 | |
Yes | 66.2% | |
No | 28.3% | |
Cholangitis | <0.0001 | |
Yes | 87.6% | |
No | 48.6% | |
Pruritus | <0.0001 | |
Yes | 74.4% | |
No | 51.1% | |
Coagulopathy | 0.05 | |
Yes | 76.5% | |
No | 52.5% | |
Tumor Characteristics and Treatment | ||
Stage (N=2,496) | 0.0002 | |
Localized | 44.1% | |
Regional | 55.0% | |
Distant | 47.8% | |
Differentiation | 0.49 | |
Poor | 53.7% | |
Nodal status (regional disease only) (N=1,979) | 0.22 | |
Positive | 55.7% | |
Negative | 52.7% | |
Neoadjuvant therapy | 0.008 | |
Yes | 63.3% | |
No | 52.0% | |
Gastroenterologist visit before surgeon visit | <0.0001 | |
Yes | 60.7% | |
No | 41.2% |